MEDICINE AGENT FOR PROMOTING SECRETION OF GLP-1 AND RESTRAINING SECRETION OF GIP

摘要

PURPOSE: A medicine which promotes the secretion of GLP-1 and restrains the secretion of GIP is provided to promoting the desired GLP-1 while restraining the secretion of GIP which is not desirable for the treatment of the impaired glucose tolerance and the prevention of diabetes. CONSTITUTION: A medicine is for promoting the secretion of GLP-1(glucagon like peptide 1) and restraining the secretion of GIP(Glucose dependent insulin secretion stimulation polypeptide). The medicine contains the none-competitive type inhibitor of the sucroclastic enzyme as an effective ingredient, and the none-competitive type inhibiter is the L-arabinose, D-xylose, and/or D-tagatose. The combination ratio of the non-competitive type inhibitor is 4.5-99 wt % in case of L-arabinose and D-xylose and 25-99wt% in case of D-tagatose. The medicine is taken with sucrose or food containing sucrose, and is taken within 90 minutes before the intake of the sucrose or the food. The food containing sucrose is Japanese style snacks, western style snacks, dairy products, drink, or beverage. [Reference numerals] (AA) Active GLP-1; (BB) Sucrose; (CC) Sucrose + arabinose; (DD) Arabinose; (EE) Time(minutes)